Call it death by disclosure.
After nearly 30 years in which prescription drug ads have become a fixture on television, the Trump administration is attempting a crafty maneuver to largely rid the airwaves of these promotions.
To what extent the gambit will work is uncertain. But the effort revives an important debate that I think is worth having.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.